Cat. No. | Product name | CAS No. |
DC11709 |
CB-1158
CB-1158 (INCB-01158) is a potent, selective, oral available Arginase inhibitor with IC50 of 98 nM. |
2095732-06-0 |
DC8840 |
CB-5083
Featured
CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models . |
1542705-92-9 |
DC8042 |
CB-839(Telaglenastat)
Featured
CB-839 is a potent, selective, reversible and orally bioavailable inhibitor of human glutaminase. |
1439399-58-2 |
DC10617 |
CBL0137
Featured
CBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM. |
1197996-80-7 |
DC8377 |
CC-115
Featured
CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. |
1228013-15-7 |
DC10146 |
CC-122(Avadomide)
Featured
CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity.CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL. |
1015474-32-4 |
DC8497 |
CC-223
Featured
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM). |
1228013-30-6 |
DC7096 |
CC-401
Featured
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. |
1438391-30-0 |
DC10206 |
CCX140
CCX140 is a potent CCR2 antagonist. |
1100318-47-5 |
DC3170 |
Cediranib
Featured
Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor with IC50 of 0.5 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. |
288383-20-0 |
DCAPI1024 |
Cefditoren pivoxil
Cefditoren pivoxil |
117467-28-4 |
DC10357 |
Cenerimod
Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM. |
1262414-04-9 |
DC9765 |
CERC-501(LY-2456302,Aticaprant)
Featured
CERC-501(LY-2456302) is a potent, selective antagonist of the kappa opioid receptor (KOR) (Ki = 0.81 nM vs. 24.0 nM and 155 nM for the μ-opioid receptor (MOR) and δ-opioid receptor (DOR), respectively. |
1174130-61-0 |
DC9154 |
Cetirizine 2HCl
Cetirizine 2Hcl, a second-generation antihistamine, is a major metabolite of hydroxyzine, and a racemic selective H1 receptor inverse agonist used in the treatment of allergies, hay fever, angioedema, and urticaria. |
83881-52-1 |
DC10440 |
Namodenoson (CF-102)
Featured
CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. target: A3 adenosine receptor agonist; |
163042-96-4 |
DC8471 |
CGS 21680 hydrochloride
Featured
CGS 21680 hydrochloride is an A2A adenosine receptor agonist (Ki = 27 nM). |
124431-80-7 |
DC8418 |
CH5183284 (Debio-1347)
Featured
CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1. |
1265229-25-1 |
DC7383 |
CH5424802(Alectinib)
Featured
CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation. |
1256580-46-7 |
DC8728 |
CH5424802(Alectinib HCl)
Featured
CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation. |
1256589-74-8 |
DC7978 |
Tucidinostat(Chidamide)
Featured
Chidamide is a class I HDAC inhibitor with IC50s of 95/160/67/733 nM for HDAC1/2/3/8; also inhibits HDAC10/11(IC50=78/432 nM); no inhibition on HDAC4/5/7/9/6(IC50>30 uM). |
743420-02-2 |
DC8116 |
Tosedostat (CHR2797)
Featured
CHR-2797 is an aminopeptidase inhibitor, with IC50 values of 100 nM for LAP3 (LAP), 150 nM for PSAP (PuSA) and 220 nM for CD13 (Aminopeptidase N). |
238750-77-1 |
DC10341 |
CHZ868
CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell. |
1895895-38-1 |